Argo Biopharma begins patient dosing in phase II trials of siRNA therapy BW-40202: Shanghai, China Wednesday, April 22, 2026, 15:00 Hrs [IST] Argo Biopharmaceutical Co., Ltd. (Arg ...

The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...

Panakeia ("the Company"), the world's first in silico multi-omics company, today unveiled landmark pathway activation data in cancers at the American Association for Cancer Research (AACR) Annual ...

EnviroGold Global Limited (TSX-V: NVRO | OTCQB: ESGLF | FSE: YGK) (“EnviroGold” or the “Company”), a clean technology company focused on the recovery of precious and critical metals from mine waste ...

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced preclinical data highlighting an ...

A study issued by M42 in partnership with the Department of Health – Abu Dhabi demonstrates how genomics enables prevention ...

The government of Kenya, in partnership with the United Nations Development Programme, has launched the Biodiversity Finance ...

Interac Corp. (Interac) is expanding the Interac® verification service through a new collaboration with National Bank of ...

"It has effectively resolved the perceived trade-off between rural employment, income growth and ecological protection," Wu ...

Partnership enables timely access to botensilimab plus balstilimab through France’s government-reimbursed Autorisation d’Accès Compassionnel (AAC) pathway and paid named-patient programs (NPP) in ...

For years, pomegranates have enjoyed a reputation as a "heart-healthy" fruit. As a cardiovascular researcher, I have often ...